Revlimid (lenalidomide)
An approved treatment for Multiple Myeloma.
Drug facts
The same compound appears under different names depending on the context. Here is how to identify Lenalidomide wherever you encounter it, plus the key facts at a glance.
- Generic name
- Lenalidomide
- Brand name
- Revlimid
- Development code
- CC-5013
- Drug class
- Immunomodulatory drug (thalidomide analogue)
- Manufacturer
- Bristol Myers Squibb (Celgene Corporation); generic lenalidomide is made by several companies
- How it's taken
- Capsule by mouth once daily, on days 1 to 21 of 28-day cycles with dexamethasone or every day as maintenance
Revlimid (lenalidomide) is a daily capsule related to thalidomide for adults with multiple myeloma, taken with dexamethasone or alone as maintenance after transplant[1].
- The FDA first approved Revlimid for myeloma on June 29, 2006, widened the approval to include newly diagnosed myeloma on February 17, 2015, and added maintenance after transplant on February 22, 2017[4][5][6].
- In the FIRST trial of 1,623 people with newly diagnosed myeloma who were not transplant candidates, Revlimid with dexamethasone until progression gave a median progression-free survival of 25.5 months versus 21.2 months with melphalan, prednisone and thalidomide[1][17].
- Revlimid carries a boxed warning for birth defects, low blood counts and blood clots, and it can only be prescribed and dispensed through the Lenalidomide REMS safety program[1][8].
- Generic lenalidomide capsules from many companies are FDA approved and rated as substitutable for Revlimid[9].
We'll email you when Revlimid's FDA label changes, when the FDA acts on it, and when new trials for Multiple Myeloma open. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Where Lenalidomide fits
The Revlimid label covers 2 myeloma uses: with dexamethasone for adults with multiple myeloma at any stage, and alone as maintenance after an autologous stem cell transplant[1]. Lenalidomide is also a named partner in other medicines' myeloma labels, including Darzalex Faspro with bortezomib and dexamethasone for newly diagnosed myeloma, and Kyprolis and Ninlaro combinations for myeloma that has been treated before[21][22][23]. Pomalyst, a related drug, is approved for myeloma after treatment that included lenalidomide[20]. Outside myeloma, Revlimid is approved for deletion 5q MDS, mantle cell lymphoma, follicular lymphoma and marginal zone lymphoma, and its label says it is not recommended for chronic lymphocytic leukemia outside trials[1].
How Lenalidomide works
Lenalidomide is a close chemical relative of thalidomide, and its label describes it as having immune-boosting, blood-vessel-blocking and anticancer properties[1]. Inside cells, lenalidomide attaches to a protein called cereblon, which is part of the cell's system for tagging proteins for disposal[1].
With lenalidomide attached, cereblon marks other proteins for breakdown, including Ikaros and Aiolos, 2 proteins myeloma cells depend on[1]. The label lists several effects that follow:
In laboratory tests, lenalidomide and dexamethasone (a steroid) together slowed myeloma cell growth more than either alone, which is one reason the 2 are commonly paired[1].
Side effects and safety
- Embryo-fetal toxicity. Contraindicated in pregnancy; pregnancy tests and 2 forms of birth control for women who can become pregnant, condoms for men, from 4 weeks before until 4 weeks after treatment.
- Hematologic toxicity. Low neutrophils and platelets are common; severe neutropenia in up to 59% and severe thrombocytopenia in up to 38% in the maintenance trials.
- Venous and arterial thromboembolism. Deep vein clots in 7.4% and lung clots in 3.7% with dexamethasone in previously treated myeloma; clot-prevention medicine is recommended.
- Second primary malignancies. More AML, MDS and other cancers; blood cancers in 7.5% on maintenance versus 3.3% on placebo.
- Increased mortality with pembrolizumab. Adding pembrolizumab to a thalidomide analogue and dexamethasone raised deaths in 2 trials and is not recommended outside trials.
- Hepatotoxicity. Liver failure, including deaths, has occurred; liver enzymes are checked periodically.
- Severe cutaneous reactions. Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS can be fatal; Revlimid is stopped permanently for these.
- Tumor lysis syndrome. Fatal cases have occurred; people with a high tumor burden are monitored closely.
- Impaired stem cell mobilization. Fewer stem cells may be collected after more than 4 cycles, so early referral to a transplant center is advised.
- Thyroid disorders. Both underactive and overactive thyroid have been reported; thyroid function is checked before and during treatment.
- Hypersensitivity. Angioedema and anaphylaxis have been reported; Revlimid is stopped permanently if they occur.
- Increased mortality in CLL. Revlimid is not recommended for chronic lymphocytic leukemia outside trials after higher death rates in a CLL study.
- Complete blood counts weekly for the first 2 cycles, on days 1 and 15 of cycle 3, then every 4 weeks
- Pregnancy tests for women who can become pregnant, as the REMS requires
- Signs of blood clots such as shortness of breath, chest pain, or arm or leg swelling
- Liver enzymes periodically
- Thyroid function before and during treatment
- Kidney function, which sets the starting dose
- Skin rashes and signs of a second cancer
Revlimid carries a boxed warning, the FDA's strongest, for 3 risks: harm to an unborn baby, low blood counts, and blood clots in veins and arteries[1].
Birth defects: lenalidomide caused limb abnormalities in a monkey study similar to thalidomide's effects in humans, so Revlimid must never be taken during pregnancy[1]. Women who can become pregnant need 2 negative pregnancy tests before starting and must use 2 forms of birth control (or not have heterosexual sex) from 4 weeks before until 4 weeks after treatment[1].
Men must use a latex or synthetic condom with partners who could become pregnant during treatment and for 4 weeks after, even after a vasectomy, because lenalidomide is present in semen[1].
Blood clots: in trials of people with myeloma after at least 1 prior therapy, deep vein clots occurred in 7.4% on Revlimid with dexamethasone versus 3.1% on dexamethasone alone, and lung clots in 3.7% versus 0.9%[1]. Heart attack and stroke were also more common, so the label recommends medicine to prevent clots, chosen based on each person's risk[1].
Other warnings on the label:
- Low neutrophils and platelets; in the maintenance trials, severe (grade 3 or 4) neutropenia occurred in up to 59% and severe thrombocytopenia in up to 38%[1]
- Second cancers, notably AML and MDS; after transplant, blood cancers occurred in 7.5% on Revlimid maintenance versus 3.3% on placebo[1]
- Liver injury, including fatal liver failure, with serious liver events in 2% of people with myeloma[1]
- Severe skin reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS, which can be fatal[1]
- Tumor lysis syndrome, thyroid problems and allergic reactions including angioedema and anaphylaxis[1]
- Fewer stem cells collected for transplant after more than 4 cycles of Revlimid[1]
- Higher death rates in trials that added pembrolizumab to a thalidomide analogue and dexamethasone, a combination the label does not recommend outside trials[1]
In myeloma trials, the most common side effects (20% or more) included diarrhea, tiredness, anemia, constipation, low neutrophils, leg and ankle swelling, trouble sleeping, muscle cramps, back pain, nausea, fever, upper respiratory infections, cough, rash and low platelets[1]. In the FIRST trial, infections occurred in 75% of people on continuous Revlimid with dexamethasone versus 56% on melphalan, prednisone and thalidomide, and new cataracts rose to 9.6% by the second year of treatment[1].
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Lenalidomide
Revlimid is a capsule swallowed whole with water once a day, at about the same time each day, with or without food[1]. The label says not to open, break or chew the capsules[1].
Myeloma schedules on the current label:
- With dexamethasone: 25mg once daily on days 1 to 21 of each 28-day cycle, continued until the myeloma progresses or side effects become unacceptable[1]
- Maintenance after an autologous stem cell transplant: 10mg once daily on all 28 days of each cycle, which can rise to 15mg after 3 cycles if tolerated[1]
- Maintenance starts once blood counts have recovered after the transplant[1]
The starting dose is lower for people with reduced kidney function, for example 10mg daily when creatinine clearance is 30 to 60mL/min with dexamethasone, and doses are paused and lowered for low blood counts[1]. For people who may have a transplant, the label says stem cells should be collected within 4 cycles of a Revlimid-containing treatment[1].
Revlimid is available only through the Lenalidomide REMS, a restricted program required by the FDA because of the risk of birth defects[1][8]. Prescribers and pharmacies must be certified, and each patient signs a Patient-Physician Agreement Form and completes a survey before each prescription[1][8]. Each prescription is limited to a 28-day supply with no refills and no phone orders, and the pharmacy can fill it only when 7 days or less remain on the last supply[8].
Patients may not donate blood during treatment or for 4 weeks after, and unused capsules go back to the REMS, the prescriber or the dispensing pharmacy[1][8]. The label lists the program at www.lenalidomiderems.com and 1-888-423-5436[1].
Availability and cost
Generic versions may be available at a lower cost. Ask your pharmacist.
Help paying for Revlimid
With private insurance, the drugmaker's copay card can lower what you pay for Revlimid. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. Of the 5 charity funds for Multiple Myeloma, 1 was open on October 26, 2026. Pick your insurance below to see which offers fit you.
- Copay help
The BMS Access Support Co-Pay Assistance Program helps commercially insured patients prescribed Revlimid with deductibles, co-pays or co-insurance. Eligible patients may pay as little as $0 per one-month supply, subject to a maximum benefit. Not available to patients with Medicare, Medicaid, MediGap, CHAMPVA, TRICARE, VA or DoD coverage, or to cash-paying patients.
For: private insurance · source - Other support
BMS Access Support may provide information about, or make a referral to, independent charitable foundations that may help with costs. These foundations are independent of Bristol Myers Squibb and set their own eligibility rules.
For: Medicare, Medicaid, TRICARE, no insurance · source - Insurance and case manager help
BMS Access Support offers coverage and access assistance, help finding local support resources and language translation help. Live support at 1-800-861-0048, 8 AM to 8 PM ET, Monday through Friday.
The official page does not say who qualifies. Ask the program. · source
Good to know: The co-pay terms say monthly, annual or per-claim maximum benefits may apply and can vary with a patient's plan, including co-pay maximizer programs; no dollar cap is published. The Revlimid co-pay offer is not valid for Massachusetts residents, or for California residents unless they have completed any step therapy or prior authorization their plan requires. Generic lenalidomide is sold by other companies that are not part of this program, so ask your cancer center or specialty pharmacy which version your plan covers.
Charity funds for Multiple Myeloma
- From a charity · HealthWell FoundationMultiple Myeloma (Medicare Access) fundOpen
Pays for: Copays, premiums or other treatment costs. Medicare patients only.
Clinical trial results
Revlimid's first myeloma approval rested on 2 placebo-controlled trials, MM-009 (NCT00056160) and MM-010 (NCT00424047), in people whose myeloma had been treated before[10][11][1]. Both compared Revlimid plus high-dose dexamethasone with dexamethasone alone[1].
Results from the label:
The FIRST trial, also called MM-020 (NCT00689936), randomized 1,623 people with newly diagnosed myeloma who were not transplant candidates to 3 arms[12][1][17]. Revlimid with low-dose dexamethasone given until progression had a median progression-free survival of 25.5 months, versus 20.7 months when given for 18 cycles and 21.2 months with melphalan, prednisone and thalidomide (MPT)[1]. Responses occurred in 75.1% versus 62.3% with MPT, and in an interim analysis the hazard ratio for overall survival versus MPT was 0.75[1].
The maintenance approval came from 2 placebo-controlled trials after transplant, CALGB 100104 (NCT00114101, 460 people) and IFM 2005-02 (NCT00430365, 614 people)[13][14][1]. In the updated analysis, median progression-free survival was 68.6 versus 22.5 months in the first study and 46.3 versus 23.8 months in the second[1][18][19]. Median overall survival was 111.0 versus 84.2 months in the first study, and 105.9 versus 88.1 months in the second, where the difference was not statistically clear (hazard ratio 0.90)[1].
Development history
Lenalidomide was developed by Celgene under the code CC-5013, and Drugs@FDA now lists Bristol Myers Squibb, which completed its purchase of Celgene on November 20, 2019, as the holder of the US application[10][2][24].
Myeloma milestones from FDA records:
- June 29, 2006: accelerated approval with dexamethasone for myeloma after at least 1 prior therapy, based on MM-009 and MM-010, with a safety plan called RevAssist[4]
- August 3, 2010: the FDA approved the first formal Revlimid REMS[5]
- February 17, 2015: approval with dexamethasone for patients with multiple myeloma, which added newly diagnosed myeloma based on FIRST[5]
- February 22, 2017: approval as maintenance after autologous stem cell transplant[6]
- May 21, 2021: the brand-only Revlimid REMS was replaced by the Lenalidomide REMS, a shared program that covers Revlimid and generic lenalidomide[8]
- April 27, 2026: the most recent update to the Lenalidomide REMS, which aligned it with the Thalomid and pomalidomide programs[8]
Revlimid's very first approval, on December 27, 2005, was for anemia in a type of myelodysplastic syndrome (MDS) with a deletion 5q change[3][2]. It is also approved for mantle cell lymphoma (2013) and, with rituximab, for follicular and marginal zone lymphoma (2019)[2][1]. Those uses are outside this page's myeloma focus.
The first generic lenalidomide was approved on May 21, 2021, and Drugs@FDA now lists 20 generic versions rated AB, meaning substitutable for Revlimid[9]. Of those, 19 carry a prescription marketing status and 1 is listed as discontinued[9]. The prescribing information on DailyMed was last revised in March 2023, and a July 22, 2026 FDA approval added a distinct color for each capsule strength on the container labels[1][7].
Explore Multiple Myeloma trials
Other Multiple Myeloma treatments
Revlimid belongs to the immunomodulatory drug class with thalidomide and Pomalyst (pomalidomide), all chemical relatives that share embryo-fetal REMS programs[8][20]. Lenalidomide is often combined with drugs from other classes, such as proteasome inhibitors like Kyprolis and Ninlaro and anti-CD38 antibodies like Darzalex Faspro[22][23][21]. In the FIRST trial, continuous Revlimid with dexamethasone was compared directly with MPT, a regimen containing thalidomide, in newly diagnosed myeloma, and the label reports longer progression-free survival with the Revlimid arm[1].
Common questions about Lenalidomide
▸What is Lenalidomide (Revlimid)?
Revlimid (lenalidomide) is a daily capsule related to thalidomide for adults with multiple myeloma, taken with dexamethasone or alone as maintenance after transplant[1]. The FDA first approved Revlimid for myeloma on June 29, 2006, widened the approval to include newly diagnosed myeloma on February 17, 2015, and added maintenance after transplant on February 22, 2017[4][5][6]. In the FIRST trial of 1,623 people with newly diagnosed myeloma who were not transplant candidates, Revlimid with dexamethasone until progression gave a median progression-free survival of 25.5 months versus 21.2 months with melphalan, prednisone and thalidomide[1][17]. Revlimid carries a boxed warning for birth defects, low blood counts and blood clots, and it can only be prescribed and dispensed through the Lenalidomide REMS safety program[1][8]. Generic lenalidomide capsules from many companies are FDA approved and rated as substitutable for Revlimid[9].
▸How does Lenalidomide work?
Lenalidomide is a close chemical relative of thalidomide, and its label describes it as having immune-boosting, blood-vessel-blocking and anticancer properties[1]. Inside cells, lenalidomide attaches to a protein called cereblon, which is part of the cell's system for tagging proteins for disposal[1].
With lenalidomide attached, cereblon marks other proteins for breakdown, including Ikaros and Aiolos, 2 proteins myeloma cells depend on[1]. The label lists several effects that follow:
- Myeloma cells stop multiplying and die (apoptosis)[1]
- T cells and natural killer (NK) cells, the immune cells that attack cancer, increase in number and activity[1]
- Inflammatory signals such as TNF-alpha and IL-6 made by other immune cells are reduced[1]
In laboratory tests, lenalidomide and dexamethasone (a steroid) together slowed myeloma cell growth more than either alone, which is one reason the 2 are commonly paired[1].
▸What are the side effects of Lenalidomide?
Revlimid carries a boxed warning, the FDA's strongest, for 3 risks: harm to an unborn baby, low blood counts, and blood clots in veins and arteries[1].
Birth defects: lenalidomide caused limb abnormalities in a monkey study similar to thalidomide's effects in humans, so Revlimid must never be taken during pregnancy[1]. Women who can become pregnant need 2 negative pregnancy tests before starting and must use 2 forms of birth control (or not have heterosexual sex) from 4 weeks before until 4 weeks after treatment[1]. Men must use a latex or synthetic condom with partners who could become pregnant during treatment and for 4 weeks after, even after a vasectomy, because lenalidomide is present in semen[1].
Blood clots: in trials of people with myeloma after at least 1 prior therapy, deep vein clots occurred in 7.4% on Revlimid with dexamethasone versus 3.1% on dexamethasone alone, and lung clots in 3.7% versus 0.9%[1]. Heart attack and stroke were also more common, so the label recommends medicine to prevent clots, chosen based on each person's risk[1].
Other warnings on the label: Low neutrophils and platelets; in the maintenance trials, severe (grade 3 or 4) neutropenia occurred in up to 59% and severe thrombocytopenia in up to 38%[1] Second cancers, notably AML and MDS; after transplant, blood cancers occurred in 7.5% on Revlimid maintenance versus 3.3% on placebo[1] Liver injury, including fatal liver failure, with serious liver events in 2% of people with myeloma[1] Severe skin reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS, which can be fatal[1] Tumor lysis syndrome, thyroid problems and allergic reactions including angioedema and anaphylaxis[1] Fewer stem cells collected for transplant after more than 4 cycles of Revlimid[1] Higher death rates in trials that added pembrolizumab to a thalidomide analogue and dexamethasone, a combination the label does not recommend outside trials[1]
In myeloma trials, the most common side effects (20% or more) included diarrhea, tiredness, anemia, constipation, low neutrophils, leg and ankle swelling, trouble sleeping, muscle cramps, back pain, nausea, fever, upper respiratory infections, cough, rash and low platelets[1]. In the FIRST trial, infections occurred in 75% of people on continuous Revlimid with dexamethasone versus 56% on melphalan, prednisone and thalidomide, and new cataracts rose to 9.6% by the second year of treatment[1].
▸How is Lenalidomide taken?
Revlimid is a capsule swallowed whole with water once a day, at about the same time each day, with or without food[1]. The label says not to open, break or chew the capsules[1].
Myeloma schedules on the current label:
- With dexamethasone: 25mg once daily on days 1 to 21 of each 28-day cycle, continued until the myeloma progresses or side effects become unacceptable[1]
- Maintenance after an autologous stem cell transplant: 10mg once daily on all 28 days of each cycle, which can rise to 15mg after 3 cycles if tolerated[1]
- Maintenance starts once blood counts have recovered after the transplant[1]
The starting dose is lower for people with reduced kidney function, for example 10mg daily when creatinine clearance is 30 to 60mL/min with dexamethasone, and doses are paused and lowered for low blood counts[1]. For people who may have a transplant, the label says stem cells should be collected within 4 cycles of a Revlimid-containing treatment[1].
Revlimid is available only through the Lenalidomide REMS, a restricted program required by the FDA because of the risk of birth defects[1][8]. Prescribers and pharmacies must be certified, and each patient signs a Patient-Physician Agreement Form and completes a survey before each prescription[1][8]. Each prescription is limited to a 28-day supply with no refills and no phone orders, and the pharmacy can fill it only when 7 days or less remain on the last supply[8]. Patients may not donate blood during treatment or for 4 weeks after, and unused capsules go back to the REMS, the prescriber or the dispensing pharmacy[1][8]. The label lists the program at www.lenalidomiderems.com and 1-888-423-5436[1].
▸Is Lenalidomide FDA approved?
Yes, Lenalidomide (Revlimid) is FDA approved (2006) for the treatment of Multiple Myeloma.
▸Is Revlimid chemotherapy?
The Revlimid label does not call it chemotherapy; it describes lenalidomide as a thalidomide analogue with immune-boosting, blood-vessel-blocking and anticancer effects[1].
How it works: Lenalidomide binds cereblon, which leads to breakdown of proteins myeloma cells need and activates T cells and NK cells[1].
Form: Revlimid is a capsule taken by mouth at home, usually with dexamethasone or alone as maintenance[1].
Source: Revlimid prescribing information (DailyMed)
▸Is there a generic for Revlimid?
Yes, generic lenalidomide capsules are FDA approved and rated AB, meaning a pharmacy can substitute them for Revlimid[9].
First approval: The FDA approved the first generic lenalidomide on May 21, 2021[9].
How many: Drugs@FDA lists 20 generic versions, 19 with a prescription marketing status and 1 discontinued[9].
Same safety program: Generic lenalidomide is dispensed through the same Lenalidomide REMS as Revlimid[8].
Source: Drugs@FDA (openFDA) records for lenalidomide; FDA REMS database, Lenalidomide REMS
▸Why is Revlimid only available through a REMS program?
Revlimid can cause severe birth defects, so the FDA requires it to be prescribed and dispensed only through the Lenalidomide REMS[1].
Prescribers and pharmacies: Both must be certified in the program[1].
Patients: Each patient signs a Patient-Physician Agreement Form and completes a survey, and women who can become pregnant have regular pregnancy tests[8].
Supply limits: Each prescription covers no more than 28 days, with no refills or phone orders[8].
Contact: The label lists www.lenalidomiderems.com and 1-888-423-5436[1].
Source: Revlimid prescribing information (DailyMed); FDA REMS database, Lenalidomide REMS
▸How long do you take Revlimid for maintenance after a transplant?
The Revlimid label says maintenance continues until the myeloma progresses or side effects become unacceptable, with no fixed end date[1].
Dose: The label starts at 10mg daily on all 28 days of each cycle, rising to 15mg after 3 cycles if tolerated[1].
Trial results: In CALGB 100104, median progression-free survival was 68.6 months on Revlimid versus 22.5 months on placebo[1].
Who decides: The right length of treatment for any one person is a question for their myeloma team.
Source: Revlimid prescribing information (DailyMed)
▸Does Revlimid cause blood clots?
Yes, blood clots are part of Revlimid's boxed warning, especially when it is taken with dexamethasone[1].
Numbers: In previously treated myeloma, deep vein clots occurred in 7.4% versus 3.1%, and lung clots in 3.7% versus 0.9%, compared with dexamethasone alone[1].
Prevention: The label recommends clot-prevention medicine chosen according to each person's risk[1].
Warning signs: The label lists shortness of breath, chest pain, and arm or leg swelling as reasons to seek care right away[1].
Source: Revlimid prescribing information (DailyMed)
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- U.S. National Library of Medicine, DailyMed (Celgene Corporation, a Bristol-Myers Squibb company) · 2023-03. REVLIMID (lenalidomide) capsules, full prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be
- U.S. Food and Drug Administration · 2026-11. Drugs@FDA: REVLIMID, NDA 021880, approval history. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021880
- U.S. Food and Drug Administration · 2005-12-27. NDA 21-880 approval letter: Revlimid (lenalidomide) for deletion 5q myelodysplastic syndromes. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/021880rev2.pdf
- U.S. Food and Drug Administration · 2006-06-29. NDA 21-880/S-001 approval letter: Revlimid with dexamethasone for multiple myeloma after at least 1 prior therapy (Subpart H). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/021880s001LTR.pdf
- U.S. Food and Drug Administration · 2015-02-17. NDA 021880/S-041 supplement approval and REMS modification: Revlimid with dexamethasone for multiple myeloma. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/021880Orig1s041ltr.pdf
- U.S. Food and Drug Administration · 2017-02-22. NDA 021880/S-049 supplement approval: maintenance following autologous hematopoietic stem cell transplantation. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/021880Orig1s049ltr.pdf
- U.S. Food and Drug Administration · 2026-07-22. NDA 021880/S-070 supplement approval: container label color for each strength. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/021880Orig1s070ltr.pdf
- U.S. Food and Drug Administration · 2026-04-27. Approved Risk Evaluation and Mitigation Strategies: Lenalidomide Shared System REMS (last update April 27, 2026). https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=RemsDetails.page&REMS=410
- U.S. Food and Drug Administration (openFDA) · 2026-11-04. Drugs@FDA records for all lenalidomide applications, with approval dates, marketing status and therapeutic equivalence codes. https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:LENALIDOMIDE&limit=100
- ClinicalTrials.gov · 2026-11. CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma. https://clinicaltrials.gov/study/NCT00056160
- ClinicalTrials.gov · 2026-11. A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma. https://clinicaltrials.gov/study/NCT00424047
- ClinicalTrials.gov · 2026-11. Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma (FIRST). https://clinicaltrials.gov/study/NCT00689936
- ClinicalTrials.gov · 2026-11. Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant. https://clinicaltrials.gov/study/NCT00114101
- ClinicalTrials.gov · 2026-11. Maintenance Therapy Using Lenalidomide in Myeloma (IFM2005-02). https://clinicaltrials.gov/study/NCT00430365
- New England Journal of Medicine · 2007-11-22. Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America. https://doi.org/10.1056/NEJMoa070596
- New England Journal of Medicine · 2007-11-22. Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma. https://doi.org/10.1056/NEJMoa070594
- New England Journal of Medicine · 2014-09-04. Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. https://doi.org/10.1056/NEJMoa1402551
- New England Journal of Medicine · 2012-05-10. Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma. https://doi.org/10.1056/NEJMoa1114083
- New England Journal of Medicine · 2012-05-10. Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma. https://doi.org/10.1056/NEJMoa1114138
- U.S. National Library of Medicine, DailyMed (Celgene Corporation, a Bristol-Myers Squibb company) · 2025-02. POMALYST (pomalidomide) capsules, full prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66
- U.S. National Library of Medicine, DailyMed (Janssen Biotech, Inc.) · 2026-09. DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) injection, full prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bb241af-4299-4373-8762-2d6709515db0
- U.S. National Library of Medicine, DailyMed (Onyx Pharmaceuticals, Inc., an Amgen subsidiary) · 2025-06. KYPROLIS (carfilzomib) for injection, full prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea66eb30-e665-4693-99a1-a9d3b4bbe2d6
- U.S. National Library of Medicine, DailyMed (Takeda Pharmaceuticals America, Inc.) · 2026-08. NINLARO (ixazomib) capsules, full prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=038f2461-834b-4488-9ebd-863c83eef5a7
- Bristol-Myers Squibb (via BioSpace) · 2019-11-20. Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company. https://www.biospace.com/article/releases/bristol-myers-squibb-completes-acquisition-of-celgene-creating-a-leading-biopharma-company
- Bristol Myers Squibb · 2026-11. BMS Access Support: Co-Pay and Financial Support Options (Revlimid co-pay program). https://www.bmsaccesssupport.com/patient/co-pay-financial-support